Trademark: 79028077
Word
PAIONEERING
Status
Dead
Status Code
402
Status Date
Wednesday, May 11, 2016
Serial Number
79028077
Mark Type
5000
Filing Date
Thursday, May 11, 2006
Published for Opposition
Tuesday, November 4, 2008
Abandoned Date
Wednesday, May 11, 2016

Trademark Owner History
Paion Deutschland GmbH - Owner At Publication

Classifications
1 Research reagents; biochemical preparations for scientific purposes
5 Pharmaceutical preparations, namely, pharmaceutical preparations derived from living organism proteins and peptides for treatment and diagnosis of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; pharmaceutical anti-inflammatory preparations; pharmaceutical nutraceutical preparations for the treatment of strokes, neuron damage, thrombotic diseases, tumors, cancer, heart disease including heart failure, circulation disorders, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; blood clotting test kits comprised of medical diagnostic reagents; medical and clinical diagnostic reagents for clinical or medical laboratory use; pharmaceutical preparations, namely, thrombolytic, fibrinolytic anti-coagulative, antithrombotical and neuroprotective substances for the treatment of blood clotting, cell protection and cell regeneration; products from biotechnological methods, namely, proteins for therapeutic and diagnostic use in the treatment and diagnosis of blood clotting disorders
10 Laboratory devices for medical and pharmaceutical investigations, namely, portable medical devices for conducting blood specimen analysis of the human blood clotting system and for conducting medical diagnostic tests in the nature of medical apparatus for diagnosing suspected heart attacks, strokes, thrombosis, circulations and vascular disorders, embolisms, kidney failures, liver damages, infections, viral infections, sepsis, inflammatory and neuronal disorders
41 Educational services, namely, providing seminars, educational exhibitions, correspondence courses, colloquiums, conferences, congresses, and workshops in the field of biotechnology, pharmacology, biochemistry, molecular biology, medical procedures, product research and development of medical devices and pharmaceutical preparations, research procedures, protein design diagnostics, molecular diagnostics, proteogenomic profiling, gendiagnostics
42 Database development for others; computer programming for others; performing chemical analyses for others; technical consultation in the field of biotechnology; services of a biotechnological laboratory, namely, conducting lab research for others in the field of drug research and development; pharmaceutical consulting, namely, performing pre-clinical studies, quality control; preparation of technical expert opinions in the field of chemical engineering, biology, molecular biology, pharmacology, chemistry, bio-technology, bio-chemistry, product research and development of medical devices and pharmaceutical preparations; and molecular diagnostic services of a bio-chemist, namely, product research and development services for others in the areas the treatment and diagnosis of stroke, neuron damage, thrombotic diseases, heart diseases including heart failure, circulation disorders, gene expression analysis, namely, protogenomic profiling, DNA-sequencing, drug target development and identifying, designing and analyzing therapeutic proteins, diagnostic services in the field of molecular science, comparative genome analysis, DNA-arrays including DNA-microarrays, creation of nucleic acid libraries, screening of nucleic acid libraries; performance of pre-clinical studies, namely, conducting and managing pre-clinical trials and studies of pharmaceutical, bio-technology and health care products; bio-chemical and biotechnological research and development for others, namely, bio-technical research and development regarding medical disease diagnosis and pharmacology, namely, prenatal diagnostic and identification of hereditary factors leading to diseases, identification of genes involved in the formation of cancer, identification of target molecules for cancer treatment, scientific research on and development of medical diagnostic equipment and pharmaceutical preparations and products for the treatment of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; scientific and technical consulting for others in the field of medical science and drug research, namely, identifying, designing, and developing drugs, specifically, therapeutic proteins, gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development, identification and design; medical science research services for others in the fields of prenatal diagnostics, molecular diagnostics, comparative genome analysis, DNA-arrays including DNA-microarrays, creating and screening of nucleic acid libraries, identifying hereditary factors leading to diseases, identifying genes involved in the formation of cancer, identification of target molecules for cancer treatment
Color is not claimed as a feature of the mark.
PIONEERING

Trademark Events
Dec 9, 2016
Notification Of Effect Of Abandonment Of Intl Reg E-Mailed
Dec 8, 2016
Death Of International Registration
Dec 13, 2013
New Representative At Ib Received
Oct 2, 2010
Final Decision Transaction Processed By Ib
Aug 12, 2010
Final Disposition Notice Sent To Ib
Aug 12, 2010
Final Disposition Notice Created, To Be Sent To Ib
Dec 1, 2009
Opposition Terminated No. 999999
Dec 1, 2009
Opposition Dismissed No. 999999
Aug 12, 2009
Abandonment Notice Mailed - Inter Partes Decision
Aug 12, 2009
Abandonment - After Inter Partes Decision
Aug 12, 2009
Opposition Terminated No. 999999
Aug 12, 2009
Opposition Sustained No. 999999
Jul 18, 2009
Refusal Processed By Ib
Jul 18, 2009
Notification Of Possible Opposition - Processed By Ib
Jun 23, 2009
Irregularity On Refusal From Ib
May 6, 2009
Opposition Instituted No. 999999
May 5, 2009
Opposition Notice (Ib Refusal) Sent To Ib
May 5, 2009
Opposition Notice (Ib Refusal) Created
Jan 15, 2009
Opposition Instituted No. 999999
Nov 24, 2008
Extension Of Time To Oppose Received
Nov 4, 2008
Published For Opposition
Oct 15, 2008
Notice Of Publication
Oct 1, 2008
Law Office Publication Review Completed
Sep 19, 2008
Approved For Pub - Principal Register
Sep 19, 2008
Examiner's Amendment Entered
Sep 19, 2008
Notification Of Examiners Amendment E-Mailed
Sep 19, 2008
Examiners Amendment E-Mailed
Sep 19, 2008
Examiners Amendment -Written
Sep 19, 2008
Previous Allowance Count Withdrawn
Sep 19, 2008
Approved For Pub - Principal Register
Aug 11, 2008
Attorney Revoked And/Or Appointed
Aug 11, 2008
Teas Revoke/Appoint Attorney Received
Aug 7, 2008
Teas/Email Correspondence Entered
Aug 7, 2008
Correspondence Received In Law Office
Aug 4, 2008
Teas Request For Reconsideration Received
Aug 4, 2008
Attorney Revoked And/Or Appointed
Aug 4, 2008
Teas Revoke/Appoint Attorney Received
Mar 28, 2008
Notification Of Possible Opposition - Processed By Ib
Mar 13, 2008
Notification Of Possible Opposition Sent To Ib
Mar 13, 2008
Notification Of Possible Opposition Created, To Be Sent To Ib
Feb 6, 2008
Final Refusal Mailed
Feb 5, 2008
Final Refusal Written
May 16, 2007
Amendment From Applicant Entered
May 16, 2007
Correspondence Received In Law Office
May 16, 2007
Assigned To Lie
Apr 23, 2007
Paper Received
Nov 10, 2006
Refusal Processed By Ib
Oct 24, 2006
Non-Final Action Mailed - Refusal Sent To Ib
Oct 24, 2006
Refusal Processed By Mpu
Oct 23, 2006
Non-Final Action (Ib Refusal) Prepared For Review
Oct 22, 2006
Non-Final Action Written
Oct 13, 2006
Assigned To Examiner
Oct 13, 2006
New Application Entered In Tram
Oct 12, 2006
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24